Abstract
Post-cardiac arrest brain injury remains the leading cause of mortality and morbidity in comatose survivors despite successful resuscitation. This review synthesizes contemporary evidence from the 2025 European Resuscitation Council and European Society of Intensive Care Medicine guidelines, the 2024–2025 International Liaison Committee on Resuscitation recommendations, and recent randomized controlled trials to provide clinicians with a practical framework emphasizing cerebral protection, multimodal monitoring, and reliable prognostication while minimizing premature withdrawal of life-sustaining therapy. Core interventions include targeted oxygenation with peripheral oxygen saturation between 94 and 98% and normocapnia with partial pressure of carbon dioxide between 35 and 45 mm of mercury, individualized perfusion targeting mean arterial pressure of 60–65 mm of mercury, active fever prevention with core temperature maintained at or below 37.5 degrees Celsius for 36–72 h without routine hypothermia, continuous electroencephalography monitoring with treatment of seizures but no prophylactic antiseizure drugs, short-acting sedation enabling neurological assessment, and multimodal neuroprognostication performed at least 72 h post-return of spontaneous circulation requiring concordant predictors across multiple domains. A disciplined multimodal approach utilizing precision in gas exchange and perfusion, rigorous fever prevention, electroencephalography-guided seizure management, and cautious delayed prognostication offers the optimal pathway to meaningful neurological recovery in post-cardiac arrest syndrome.
Introduction and background
The burden of post-cardiac arrest syndrome
Cardiac arrest affects over 600,000 individuals annually in the United States, with global incidence ranging from 30 to 97 per 100,000 population (1). Despite advances in resuscitation science, survival rates remain low, with only 9% of out-of-hospital cardiac arrest (OHCA) patients and 23% of in-hospital cardiac arrest (IHCA) patients surviving to discharge (2). Among survivors, hypoxic–ischemic brain injury (HIBI) represents the primary determinant of long-term outcome and accounts for the majority of deaths in successfully resuscitated patients (3).
Post-cardiac arrest syndrome (PCAS) encompasses a complex pathophysiological cascade including brain injury, myocardial dysfunction, and systemic ischemia–reperfusion response leading to multi-organ failure (4). The pathophysiology involves both primary ischemic injury during arrest and secondary reperfusion injury following return of spontaneous circulation (ROSC), characterized by excitotoxicity, inflammation, oxidative stress, and cerebral edema (5, 6).
The 2025 European Resuscitation Council (ERC) and European Society of Intensive Care Medicine (ESICM) guidelines represent a significant evolution in post-resuscitation care, incorporating recent evidence from major trials and providing refined recommendations for temperature management, hemodynamic targets, seizure control, and prognostication (7, 8). This review synthesizes these updates to provide clinicians with an evidence-based framework for optimizing neurocritical care in comatose cardiac arrest survivors.
Definition of comatose state
For this framework, ‘comatose’ is defined according to Posner et al. (9) and Plum and Posner (10) as a state of unarousable unresponsiveness in which patients do not open their eyes, obey commands, or demonstrate purposeful responses to stimulation. Operationally, this corresponds to a Glasgow Coma Scale (GCS) motor score <6 at ≥72 h post-ROSC, as specified in the 2025 ERC/ESICM guidelines (7, 8).
Rationale and objectives
The primary objective of this review is to provide a concise, evidence-based intensive care unit (ICU) roadmap to maximize neurological recovery in comatose adults post-cardiac arrest, with emphasis on the 2025 ERC/ESICM recommendations. Secondary objectives include:
Comparing the 2021 and 2025 guidelines and explaining key changes.
Appraising evidence for core management pillars including multimodal monitoring, temperature control, hemodynamic targets, and seizure management.
Highlighting emerging trends and research priorities in neuroprognostication and neuroprotection to improve long-term outcomes.
Review
Pathophysiology of hypoxic–ischemic brain injury after cardiac arrest
Understanding HIBI pathophysiology is crucial for implementing effective neuroprotective strategies. The injury process occurs in two distinct phases: primary ischemic injury during cardiac arrest and secondary reperfusion injury following ROSC, as illustrated in Figure 1 (5, 11).
Figure 1
Primary ischemic injury
During cardiac arrest, cessation of cerebral blood flow rapidly depletes neuronal adenosine triphosphate (ATP) stores within 2–4 min, leading to failure of sodium-potassium-adenosine triphosphatase pumps and subsequent neuronal depolarization (5). This triggers massive glutamate release, initiating excitotoxicity cascades. Cellular edema develops from ionic pump failure, while anaerobic metabolism produces lactic acidosis, further impairing cellular function. The duration and severity of this initial anoxic insult critically determine immediate neuronal death and subsequent secondary injury severity (8).
Secondary reperfusion injury
Paradoxically, restoration of blood flow triggers a second wave of injury through several interconnected mechanisms:
Excitotoxicity occurs through sustained glutamate receptor activation driving excessive calcium influx, activating proteases and lipases while promoting mitochondrial dysfunction and reactive oxygen species (ROS) generation (8, 12).
Inflammation develops as damage-associated molecular patterns activate microglia and recruit peripheral leukocytes, generating pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β), and interleukin-6 (IL-6) that disrupt the blood–brain barrier and amplify neuronal injury (13).
Oxidative stress manifests as a reperfusion-induced ROS burst that overwhelms antioxidant defenses, causing lipid peroxidation, protein denaturation, and deoxyribonucleic acid (DNA) damage (14).
Cerebral edema develops in both cytotoxic (intracellular swelling) and vasogenic (blood–brain barrier disruption) forms, increasing intracranial pressure and potentially reducing cerebral perfusion pressure to precipitate secondary ischemia (15).
Impaired autoregulation renders cerebral blood flow pressure-dependent, heightening vulnerability to both hypotension and hypertension (16).
Initial assessment and management in the ICU
Immediate post-resuscitation care and diagnosis
The first hours following ROSC are critical for establishing physiological stability and preventing secondary brain injury. Immediate priorities include securing the airway, optimizing ventilation and oxygenation, and achieving hemodynamic stability with continuous monitoring of vital signs (7, 17).
Etiological diagnosis
Establishing the underlying cause of cardiac arrest is critical for neuroprognostication because the etiology directly influences the extent and reversibility of hypoxic–ischemic brain injury. For example, cardiac arrest due to acute coronary occlusion treated with timely revascularization may result in better neurological outcomes compared to prolonged hypoxic arrest from primary respiratory causes. Additionally, identifying non-coronary causes such as intracranial hemorrhage, pulmonary embolism, or aortic dissection is essential as these conditions have distinct pathophysiological mechanisms and prognostic implications that must be considered when interpreting multimodal prognostic tests. Understanding the arrest etiology also guides the interpretation of biomarkers and imaging findings, ensuring that prognostication accurately reflects brain injury severity rather than confounding systemic factors.
Systematic diagnostic workup is essential to identify the underlying cause of cardiac arrest. The 2025 guidelines emphasize early comprehensive imaging, recommending whole-body computed tomography (CT) scanning for patients with OHCA or IHCA of unknown etiology to identify non-coronary causes such as pulmonary embolism, aortic dissection, or intracranial hemorrhage (7, 8, 18).
If there are signs or symptoms pre-arrest suggesting a non-coronary cause—such as headache, seizures, neurological deficits, shortness of breath in patients with known respiratory disease, or abdominal pain—the 2025 guidelines recommend performing a dual-phase whole-body CT scan including head, neck, chest, abdomen, pelvis, and CT pulmonary angiography before or after coronary angiography if indicated (7, 8).
For patients with persistent ST-elevation, immediate coronary angiography is indicated. However, in patients with ROSC after OHCA without ST-elevation on the electrocardiogram (ECG), cardiac catheterization should be delayed unless the clinical context suggests a high likelihood of acute coronary occlusion (7, 8).
Figure 2 presents the diagnostic algorithm for post-cardiac arrest patients emphasizing early identification of the underlying etiology with selective use of invasive and imaging studies based on clinical presentation.
Figure 2
Ventilation management
The 2025 guidelines recommend balanced oxygenation targeting peripheral oxygen saturation (SpO2) of 94–98%, avoiding both hypoxia and hyperoxia (7, 8). Initial 100% oxygen should be rapidly titrated, as hyperoxia can cause vasoconstriction, reduce cerebral blood flow, and increase oxidative stress (11, 19).
An important update in 2025 emphasizes that pulse oximetry can overestimate the true oxygen saturation in people with darker skin tones, and low-flow states will cause low signal quality (7, 8). This represents a critical safety consideration for accurate oxygen management.
Normocapnia is targeted with partial pressure of carbon dioxide (PaCO2) between 35 and 45 mm of mercury (mmHg) or 4.7–6.0 kilopascals (kPa) (7, 8). Hypocapnia causes cerebral vasoconstriction, reducing cerebral blood flow, while hypercapnia leads to vasodilation potentially increasing intracranial pressure in patients with impaired autoregulation (20, 21).
In patients with accidental hypothermia or treated with hypothermia, the 2025 guidelines recommend monitoring PaCO2 frequently as hypocapnia may occur (7, 8). Clinicians should use consistently either temperature-corrected or non-temperature-corrected blood gas values.
Lung-protective ventilation with tidal volumes of 6–8 milliliters per kilogram ideal body weight with appropriate positive end-expiratory pressure (PEEP) minimizes ventilator-induced lung injury and systemic inflammation (7, 8, 22) (Figure 3).
Figure 3
Core neurocritical care strategies
Hemodynamic management for cerebral protection
Maintaining adequate cerebral perfusion is fundamental to preventing secondary brain injury. Post-cardiac arrest myocardial dysfunction and systemic vasodilation frequently cause hypotension, compromising cerebral blood flow (23).
The 2025 guidelines specify a mean arterial pressure (MAP) target of 60–65 mmHg, refined from the 2021 recommendation of MAP at least 65 mmHg (7, 8). This recommendation is based on a 2023 systematic review analyzing over 1,000 patients, which found no association between higher MAP targets greater than 71 mmHg and improved survival, functional outcomes, or reduced acute kidney injury (7, 8, 24).
However, individualized targets may be appropriate based on baseline blood pressure, comorbidities, and end-organ perfusion markers. A higher MAP target might be appropriate in patients with chronic hypertension or those with persistent peripheral hypoperfusion despite MAP of 60–65 mmHg, such as oliguria or persistently elevated lactate levels (7, 8) (Figure 4).
Figure 4
While the International Liaison Committee on Resuscitation (ILCOR) found insufficient evidence to recommend a specific vasopressor, noradrenaline is generally preferred as first-line therapy due to its potent vasoconstrictive effects with minimal impact on cardiac output (7, 8, 25). Limited evidence from one small randomized trial showed identical 30-day mortality with noradrenaline versus adrenaline at 90% in both groups (7, 8, 26). In settings where noradrenaline is not available such as prehospital environments, the use of adrenaline as an infusion or as small boluses may be an accepted approach according to the 2025 guidelines (7, 8).
Continuous arterial blood pressure monitoring with frequent arterial blood gas analysis is essential. Echocardiography should be performed as soon as possible in all patients to detect any underlying cardiac pathology and quantify the degree of myocardial dysfunction (7, 8, 27).
Temperature control
Temperature management has undergone significant evolution in the 2025 guidelines, with current evidence supporting universal fever prevention rather than targeted hypothermia for all patients.
The guidelines now strongly recommend actively preventing fever by targeting core body temperature at or below 37.5 degrees Celsius for all comatose patients (7, 8). This represents a shift from previous hypothermia recommendations, based on evidence from trials such as the Targeted Temperature Management 2 (TTM2) trial demonstrating no additional benefit of targeted hypothermia at 33 degrees Celsius compared to targeted normothermia (7, 8, 28). The term “temperature control” is now preferred over “targeted temperature management” (7, 8).
The 2024 ILCOR guidelines, adopted in the 2025 ERC/ESICM guidelines, suggest:
Actively preventing fever by targeting temperature at or below 37.5 degrees Celsius (weak recommendation with low-certainty evidence).
Against routine prehospital cooling with cold fluid infusion (strong recommendation with moderate-certainty evidence).
Using temperature control devices with feedback systems when cooling is employed (7, 8, 25).
Fever prevention should continue for 36–72 h using active cooling devices with continuous temperature monitoring and feedback systems (7, 8). Surface or endovascular cooling techniques are preferred when temperature control is indicated. Importantly, comatose patients with mild hypothermia between 32 and 36 degrees Celsius after ROSC should not be actively warmed to achieve normothermia (7, 8).
Seizure management and neurological monitoring
Post-cardiac arrest seizures occur in 20–30% of comatose survivors, typically indicating severe hypoxic–ischemic encephalopathy (29). Both convulsive and non-convulsive seizures can worsen secondary brain injury by increasing metabolic demand.
Myoclonus represents the predominant seizure phenotype, characterized by sudden, brief, shock-like muscle contractions that may be generalized, focal, or multifocal (30). Onset typically occurs within 24–48 h post-arrest. Lance-Adams syndrome, emerging after consciousness recovery, predominantly affects extremities and is triggered by voluntary movement (31).
Continuous or routine electroencephalography (EEG) is recommended for at least 24–48 h to detect non-convulsive status epilepticus, which may only be apparent on electroencephalography (7, 8, 32). Standardized criteria exist for diagnosing electrographic seizures using the American Clinical Neurophysiology Society (ACNS) terminology (7, 8, 33). The 2025 guidelines emphasize recording EEG from day 1 after ROSC to predict outcome and detect seizure activity in comatose patients, with either routine EEG or continuous EEG monitoring being acceptable (7, 8).
The 2024 ILCOR recommendations, adopted by ERC/ESICM, suggest against prophylactic antiseizure medications (weak recommendation with very low-certainty evidence) but recommend treating clinically apparent and EEG-detected seizures (good practice statement) (7, 8, 25). First-line agents include levetiracetam or sodium valproate, with drug selection based on comorbidities and potential interactions (7, 8, 34).
For patients with myoclonus and benign EEG background, the 2025 guidelines recommend attempting a wake-up trial days after arrest (7, 8). The guidelines also suggest recording the EEG in the presence of myoclonic jerks to detect any associated epileptiform activity or to identify EEG signs, such as background reactivity or continuity, suggesting a potential for neurological recovery (7, 8).
General intensive care and sedation
While the primary focus of post-cardiac arrest care is cerebral protection and prognostication, comprehensive general ICU management is essential for optimizing neurological recovery. Secondary brain injury can be exacerbated by systemic complications including gastrointestinal bleeding from stress ulceration (especially in patients receiving antiplatelet or anticoagulant therapy), hyperglycemia or hypoglycemia causing metabolic derangements, malnutrition impairing neuronal repair mechanisms, and infections particularly aspiration pneumonia triggering systemic inflammation and fever. Each of these complications can confound neurological assessment and worsen secondary brain injury. Therefore, meticulous attention to these general ICU care elements is not merely supportive but directly impacts the accuracy of prognostication and the potential for meaningful neurological recovery.
Short-acting sedatives such as propofol or remifentanil are recommended to facilitate neurological assessment and wake-up trials (7, 8). Limited evidence suggests propofol-remifentanil combinations may reduce time to awakening, though with increased vasopressor requirements (7, 8, 35). The 2025 guidelines emphasize using short-acting sedative agents and daily sedation holds when treating post-cardiac arrest patients receiving mechanical ventilation, which may enable earlier clinical examination that is less confounded by sedation when assessing neurological recovery (7, 8).
While the 2025 guidelines emphasize short-acting sedation and daily sedation holds to enable neurological assessment, no standardized protocol for sedation interruption timing, duration, or monitoring currently exists. This represents an important implementation gap. Future research should establish best-practice protocols to operationalize consistent sedation holds, minimize assessment confounding, and optimize prognostic accuracy.
Routine use of neuromuscular blocking agents is discouraged unless clinically indicated for severe acute respiratory distress syndrome (ARDS), refractory status epilepticus, or prevention of shivering during temperature management, as they can mask seizures and hinder neurological assessment (7, 8, 36). The 2025 guidelines explicitly state that systematic use of neuromuscular blocking drugs in comatose post-cardiac arrest patients is not recommended (7, 8). In patients with critical hypoxemia and ARDS following cardiac arrest, the use of a neuromuscular blocker may be considered (7, 8).
Comprehensive ICU management includes:
Stress ulcer prophylaxis is especially important given the high incidence of upper gastrointestinal ulceration in post-cardiac arrest patients and the use of anticoagulant and antiplatelet drugs (7, 8).
Individualized anticoagulation should be based on general ICU recommendations (7, 8).
Strict glycemic control using standard glucose management protocols is recommended (7, 8).
Early enteral nutrition should be initiated by starting gastric feeding at low rates as trophic feeding and increasing as tolerated (7, 8).
Infection prevention strategies should be implemented (37). The 2025 guidelines recommend against routine use of prophylactic antibiotics in patients following ROSC but suggest maintaining a low threshold for giving antibiotics when there is any clinical suspicion of pneumonia (7, 8).
Pressure injury prevention: Patients are at particularly high risk for pressure injuries given prolonged immobility, compromised tissue perfusion, neurological impairment, incontinence, and nutritional vulnerability. Regular repositioning, specialized support surfaces, and systematic skin integrity assessments are essential to prevent secondary complications that may compromise rehabilitation potential.
Neurological prognostication and long-term outcomes
Accurate prognostication is crucial for guiding clinical decisions and avoiding premature withdrawal of life-sustaining therapy (WLST). The 2025 guidelines emphasize a multimodal approach performed at least 72 h post-ROSC after excluding confounding factors (7, 8).
Outcome definitions
The 2025 guidelines define:
Poor neurological outcome as death or severe disability (Cerebral Performance Category [CPC] 3–5 or modified Rankin Scale [mRS] 4–6), typically corresponding to patients who remain unconscious or severely dependent at hospital discharge or 6-month follow-up.
Favorable outcome as functional independence (CPC 1–2 or mRS 0–3), typically with return of consciousness, meaningful communication, and ability to perform activities of daily living with minimal or no assistance.
The Glasgow Outcome Scale Extended (GOSE) provides additional granularity for functional recovery assessment (38, 39).
Multimodal assessment framework
Clinical examination
Clinical examination remains a cornerstone of prognostication. The 2025 ILCOR recommendations, adopted by ERC/ESICM, suggest:
Using pupillary light reflex at 72 h or later for predicting outcomes (weak recommendation with very-low-certainty evidence) (7, 8).
Using a pupillometer when available to determine if the pupillary light reflex is absent (7, 8).
Using bilateral absence of corneal reflex at 72 h or later for predicting poor neurological outcome (weak recommendation with very low-certainty evidence) (7, 8).
The presence of myoclonus or status myoclonus within 7 days, in combination with other tests, may be used for predicting poor outcome (weak recommendation with very low-certainty evidence) (7, 8).
Status myoclonus is defined as continuous and generalized myoclonus persisting for 30 min or more within 72 h after ROSC (7, 8). Recording EEG in the presence of myoclonic jerks is recommended to detect any associated epileptiform activity (7, 8, 40).
Clinical examination is prone to interference from sedatives, opioids, or muscle relaxants, and potential confounding from residual sedation should always be considered and excluded (7, 8).
Advanced Behavioral Assessment: While the GCS motor score remains the primary threshold for prognostication (motor <6), emerging evidence emphasizes the value of specialized behavioral assessment tools beyond the GCS. The Coma Recovery Scale-Revised (CRS-R) and other validated Disorders of Consciousness (DoC) assessments can detect subtle signs of consciousness such as visual tracking, command-following, or emotional expression that the GCS may miss.
The American Academy of Neurology (41) and European Academy of Neurology (42) provide evidence-based recommendations for systematic consciousness assessment to distinguish vegetative state (unresponsive wakefulness syndrome) from minimally conscious states (42, 43). Incorporation of these structured assessments into multimodal prognostication may reduce misdiagnosis and guide rehabilitation planning, particularly when clinical examination yields indeterminate findings.
Important Limitation: Clinicians should recognize the well-documented limitations of the GCS, particularly in detecting subtle signs of consciousness across the spectrum of DoC (44). The GCS was originally designed for trauma assessment, not nuanced consciousness evaluation in hypoxic–ischemic brain injury. Combining GCS with specialized DoC assessments (CRS-R) may improve diagnostic and prognostic accuracy.
Neurophysiological assessment
The 2025 guidelines provide refined EEG criteria:
EEG patterns: Suppression or burst-suppression on EEG, defined as highly malignant patterns including suppressed background with or without periodic discharges or burst-suppression according to ACNS, being accurate indicators of poor prognosis when assessed after 24 h from ROSC (7, 8).
Important change: The guidelines recommend against using absence of EEG background reactivity alone to predict poor outcome (weak recommendation with very low-certainty evidence) (7, 8). This represents a significant change from previous practice.
SSEPs: The bilateral absence of somatosensory evoked cortical N20 potentials indicates poor prognosis after cardiac arrest (7, 8). Somatosensory evoked potentials (SSEPs) can be recorded at 24 h or later from ROSC, which changed from previous recommendations (7, 8). The guidelines recommend always considering the use of a neuromuscular blocking drug when performing SSEPs (7, 8).
Biomarker assessment
The 2025 guidelines maintain neuron-specific enolase (NSE) as the recommended biomarker, suggesting the use of serial measurements of NSE to predict outcome after cardiac arrest (7, 8).
NSE greater than 60 micrograms per liter at 48 h and/or 72 h after ROSC indicates poor prognosis (7, 8).
Increasing NSE values between 24 and 48 h or between 24/48 and 72 h further support a likely poor outcome (7, 8).
The guidelines recommend performing serial NSE samples at 24, 48, and 72 h after ROSC to detect NSE trends and minimize confounding from occasional hemolysis (7, 8).
The 2025 guidelines do not recommend using neurofilament light chain (NfL), S-100B protein, glial fibrillary acidic protein (GFAP), or serum tau protein for prognostication due to absence of consistent thresholds and mostly research-only assays (7, 8).
Brain imaging
The guidelines recommend using brain imaging studies to predict poor neurological outcome after cardiac arrest, ensuring that images are evaluated by someone with specific experience in these studies (7, 8).
CT findings: The 2025 guidelines recommend using the presence of generalized brain edema, manifested by a marked reduction of the grey matter to white matter ratio on brain CT, to predict poor neurological outcome (7, 8). The guidelines recommend repeating the brain CT if the patient is unconscious at the time of prognostication, which occurs 72–96 h after ROSC, and the first brain CT does not show signs of HIBI (7, 8).
Where specialist neuroradiology expertise is unavailable, the guidelines suggest considering telemedicine consultation for brain imaging interpretation (7, 8).
MRI findings: The guidelines recommend using extensive diffusion restriction on brain MRI at 2–7 days after ROSC to predict poor neurological outcome (7, 8). Brain imaging should only be used in centers with specific experience (7, 8).
Prognostication algorithm
The refined 2025 algorithm represents a significant evolution from 2021, with several critical updates. The 2025 guidelines recommend considering neurological prognostication in patients who are not awake and obeying commands, defined as Glasgow Coma Scale motor score less than 6, at 72 h or later after ROSC (7, 8). This represents a change from the 2021 threshold of motor response at or below 3.
Core principles include:
1 Starting prognostication assessment at 72 h or later from ROSC (7, 8).
2 Excluding major confounders including analgesics, sedation, neuromuscular blockade, hypothermia, severe hypotension, hypoglycemia, sepsis, and metabolic and respiratory derangements (7, 8).
3 Requiring a multimodal approach as no single predictor is 100% accurate (7, 8).
Poor outcome prediction: In an unconscious patient at 72 h from ROSC, in the absence of confounders, poor outcome is likely when two or more of the following predictors are present:
No pupillary and corneal reflexes at 72 h (with use of pupillometer when available).
Bilaterally absent N20 SSEP wave at 24 h or later.
Highly malignant EEG at >24 h (defined as suppression or burst-suppression off sedation).
NSE > 60 μg/L at 48 and/or 72 h, or increasing NSE between timepoints.
Status myoclonus at or before 72 h (continuous and generalized myoclonus for ≥30 min).
Diffuse and extensive anoxic injury on brain CT or MRI (7, 8).
Favorable outcome prediction: The 2025 guidelines place significant new emphasis on identifying patients with potential for recovery. When none of the criteria for poor outcome are present, the guidelines recommend assessing for signs of potential recovery including:
Glasgow Coma Scale motor score of 4 or 5 at 72–96 h after ROSC.
Normal blood values of NSE < 17 μg/L at 24–72 h after ROSC.
Continuous background without discharges on EEG within 72 h from ROSC.
Absent diffusion restriction in cortex or deep grey matter on MRI on days 2–7 after ROSC (7, 8).
In patients with two or more concordant favorable signs and no signs of poor outcome, the neurological recovery rate was greater than 80% (7, 8).
Indeterminate outcome: When neither concordant unfavorable signs nor favorable signs are present, the neurological outcome remains indeterminate (7, 8). The guidelines suggest observing and re-evaluating patients with indeterminate outcome over time to detect signs of awakening. Although prognosis is generally poor for most of these patients, neurological recovery is still possible (7, 8) (Figure 5).
Figure 5
Ethical considerations
The 2025 guidelines recommend separating discussions around withdrawal of life-sustaining treatment and the assessment of prognosis for neurological recovery (7, 8). WLST decisions should consider aspects other than brain injury such as age, comorbidity, general organ function, and the patient’s preferences (7, 8).
The guidelines recommend allocating sufficient time for communication around the level-of-treatment decision within the team and with the relatives (7, 8). After a decision on WLST, the guidelines recommend using a structured approach to shift from curative to end-of-life palliative care and considering organ donation (7, 8).
Studies have shown that premature WLST occurring before 72 h for neurological reasons is common and may result in death for patients who might have recovered to good outcome (7, 8). The 2025 guidelines strongly emphasize waiting at least 72 h and excluding all confounders before making prognostic assessments.
Rehabilitation and long-term follow-up
The 2025 guidelines place significantly enhanced emphasis on rehabilitation and long-term follow-up, recognizing that optimizing neurocritical care extends beyond the acute ICU phase.
In-hospital rehabilitation
In-hospital rehabilitation should begin as soon as patients are medically stable, including:
Physical, occupational, and speech therapy tailored to individual needs.
Active delirium management through non-pharmacological and, if necessary, pharmacological interventions.
ICU diaries documenting daily events and progress to help patients reconstruct their stay and reduce post-intensive care syndrome incidence.
The 2025 guidelines recommend implementing early mobilization, delirium management, and ICU diaries during hospitalization (7, 8).
Discharge disposition and continuum of care
Not all survivors will be candidates for direct home discharge with 3-month outpatient follow-up. The American Academy of Neurology DoC Guideline (2018) Recommendation #1 emphasizes that patients in states of poor arousal and awareness whose families are not pursuing withdrawal of life-sustaining therapy should be referred to specialized inpatient post-acute rehabilitation facilities to optimize recovery potential (41).
Discharge planning should consider the full continuum of care including:
Specialized neurorehabilitation units for patients with prolonged DoC.
Skilled nursing facilities with DoC expertise.
Acute rehabilitation hospitals for patients regaining consciousness.
Home-based rehabilitation with outpatient follow-up for functionally independent survivors.
Disposition decisions should be individualized based on level of consciousness, functional status, family preferences, and available regional resources.
Post-discharge follow-up
Post-discharge follow-up should be organized within 3 months after hospital discharge (7, 8). The guidelines recommend screening for:
Cognitive deficits including memory problems and executive dysfunction.
Emotional disturbances including anxiety, depression, and post-traumatic stress disorder (PTSD).
Physical limitations including fatigue and mobility issues.
A multidisciplinary approach involving neurologists, neuropsychologists, rehabilitation specialists, and social workers is recommended (7, 8). The guidelines recommend performing functional assessments of physical and non-physical impairments before discharge to identify rehabilitation needs and refer to early rehabilitation if indicated (7, 8). Cardiac rehabilitation should be provided as indicated by the cause of the cardiac arrest (7, 8).
Co-survivor support
Family members and caregivers, termed co-survivors, face significant burden and require:
Psychological support.
Education and resources.
Invitation to follow-up appointments.
Screening for emotional problems and impact on life roles (7, 8).
The 2025 guidelines recommend inviting co-survivors to the follow-up and asking about emotional problems and impact on life roles (7, 8).
Information should be provided for patients and co-survivors covering:
Medical subjects including cardiac disease, risk factors, medication, and implantable cardioverter-defibrillator (ICD).
Potential physical, cognitive, and emotional changes.
Fatigue, resuming daily activities, driving, work, relationships, and sexuality (7, 8).
Organ donation
The 2025 guidelines include enhanced recommendations regarding organ donation:
All patients who have restoration of circulation after cardiopulmonary resuscitation (CPR) and who subsequently progress to death should be evaluated for organ donation (7, 8).
In comatose ventilated patients who do not fulfill neurological criteria for death, if a decision to start end-of-life care and withdrawal of life support is made, organ donation should be considered when circulatory arrest occurs (7, 8).
All decisions concerning organ donation must follow local legal and ethical requirements (7, 8).
The prevalence of brain death in ventilated comatose patients with HIBI who died after CPR is 12.6%, with higher prevalence after extracorporeal cardiopulmonary resuscitation (ECPR) at 27.9% versus 8.3% (7, 8). Patients who remain comatose after resuscitation, especially when resuscitated by ECPR, should be actively evaluated for signs of brain death (7, 8). The 2025 guidelines recommend that cardiac arrest registries should report if organ donation after initial resuscitation from cardiac arrest occurred (7, 8).
Discussion: evolution from 2021 to 2025 ERC/ESICM recommendations
The 2025 ERC/ESICM guidance consolidates a fever-prevention-first strategy, strengthens a pragmatic blood pressure approach, refines EEG and seizure management and multimodal prognostication, and expands the continuum of care to co-survivors and long-term follow-up.
Table 1 presents a comprehensive comparison of key recommendations between the 2021 and 2025 European Resuscitation Council and European Society of Intensive Care Medicine guidelines for post- resuscitation care, highlighting major changes and their clinical implications.
Table 1
| Domain | 2021 recommendations | 2025 recommendations | Clinical implications |
|---|---|---|---|
 Diagnosis and initial management | |||
| Coronary angiography | Early angiography favored in suspected coronary OHCA | CHANGED More selective approach in non-ST-elevation OHCA; delayed unless high clinical suspicion of acute coronary occlusion | Reduce non-beneficial catheterization procedures; target high-yield cases; avoid delays in identifying non-coronary causes |
| Diagnostic imaging | Selective whole-body CT | NEW Strong endorsement of comprehensive CT (head-to-pelvis) when etiology unclear; dual-phase with CTPA if pre-arrest symptoms suggest non-coronary cause | Broader early search for pulmonary embolism, aortic dissection, intracranial hemorrhage; earlier diagnosis enables targeted treatment |
| Echocardiography | Considered | STRONG Routine echocardiography as soon as possible in all patients | Systematic assessment of myocardial dysfunction; guides hemodynamic management and inotrope use |
 Hemodynamic and respiratory optimization | |||
| Oxygenation target | SpO2 94–98%; avoid hyperoxia | NEW SpO2 94–98%; stronger caution against sustained hyperoxia; NEW: warning about pulse oximetry overestimating saturation in darker skin tones | Rapid FiO2 titration post-ROSC; awareness of pulse oximetry limitations; verify with ABG when available; equity in care |
| Ventilation target | Normocapnia; PaCO2 monitoring | Normocapnia maintained; frequent PaCO2 monitoring during hypothermia as hypocapnia may occur | Proactive ABG monitoring; avoid cerebral vasoconstriction from hypocapnia |
| Blood pressure target | MAP ≥65 mmHg; individualization discussed but not strongly defined | CHANGED MAP 60–65 mmHg as default; explicit individualization criteria (chronic hypertension or persistent organ hypoperfusion) | Shift from universal higher MAP to personalized moderate-intensity targets; spare vasopressor burden in many patients; reduce complication |
| Vasopressor selection | Noradrenaline generally preferred | NEW Noradrenaline first-line; adrenaline acceptable when noradrenaline unavailable (e.g., prehospital) | Pragmatic approach for resource-limited settings; maintains safety while acknowledging real-world constraints |
 Temperature management | |||
| Temperature management | TTM at 33 °C or 36 °C for 24 h; both options acceptable | PARADIGM SHIFT Universal fever prevention ≤37.5 °C for 36–72 h; no routine hypothermia; term changed to temperature control | Paradigm shift from hypothermia induction to fever prevention alone; simplified protocols; reduced shivering; less physiological stress |
| Prehospital cooling | Not specifically addressed | STRONG Recommend AGAINST routine cold fluid infusion (strong recommendation) | Avoid potential harm from prehospital cooling; focus resources on post-ROSC stabilization |
| Rewarming mild hypothermia | Not specifically addressed | NEW Do NOT actively rewarm patients with mild hypothermia (32–36 °C) after ROSC | Allow spontaneous rewarming; avoid additional physiological stress |
 Neurological management | |||
| Seizure prophylaxis | Noncommittal on prophylaxis | CHANGED Explicitly AGAINST routine prophylaxis (weak recommendation) | Avoid unnecessary medication side effects, sedation, and drug interactions; focus on treating confirmed seizures only |
| EEG timing | Continuous EEG encouraged for 24–48 h | NEW EEG from day 1 after ROSC; record during myoclonic jerks | Earlier prognostic data; better seizure detection; identify background patterns suggesting recovery potential |
| EEG for myoclonus | General recommendation to treat myoclonus | Record EEG during myoclonic jerks; attempt wake-up trial if myoclonus with benign EEG | Distinguish epileptiform from non-epileptiform myoclonus; avoid over-treatment; identify patients with recovery potential |
| Sedation strategy | Short-acting agents recommended | STRONG Strong emphasis on daily sedation holds and early neurological examination | Enable earlier prognostic clarity; potentially shorter ICU stays; facilitate wake-up assessment |
| Neuromuscular blockade | Selective use when indicated | AGAINST Explicitly AGAINST routine use; only for severe ARDS or refractory status epilepticus or shivering | Minimize risks of prolonged paralysis; allow clinical examination; enable seizure detection |
 Neurological prognostication | |||
| Prognostication threshold | GCS motor ≤3 at ≥72 h | EXPANDED GCS motor <6 at ≥72 h | Broader eligibility for prognostication; capture more patients requiring assessment; earlier family counseling |
| Pupil assessment | Clinical examination of pupillary light reflex | NEW Recommend pupillometry when available | Standardized objective measurement; reduce inter-rater variability; improve prognostic accuracy |
| Corneal reflex | Part of clinical examination | Bilateral absence at ≥72 h for poor outcome prediction (weak recommendation) | Continued use in multimodal assessment; requires careful assessment technique |
| SSEP timing | Generally recommended ≥72 h | CHANGED Acceptable from ≥24 h (changed from previous) | Earlier prognostic information; faster decision-making capability; still requires NMB during test |
| EEG reactivity | Considered poor outcome predictor | MAJOR CHANGE AGAINST using absence alone to predict poor outcome (weak recommendation) | Reduced false-positive predictions; requires integration with other modalities; major change from previous practice |
| Status myoclonus definition | Variable definitions | STANDARDIZED Defined as continuous generalized myoclonus for ≥30 min within 72 h | Standardized definition; improved consistency across centers; part of multimodal assessment |
| NSE thresholds | >60 μg/L at 48-72 h | >60 μg/L at 48 and/or 72 h; OR increasing NSE between timepoints; serial sampling at 24–48-72 h | Detect trends; minimize hemolysis confounding; improved sensitivity |
| Other biomarkers | S-100B mentioned | AGAINST Do NOT recommend NfL; S-100B; GFAP; tau (absence of consistent thresholds) | Focus on validated biomarkers (NSE); avoid premature clinical use of research markers |
| Brain CT findings | General recommendation for imaging | Generalized edema (reduced grey matter to white matter ratio) to predict poor outcome; repeat CT at 72-96 h if initial normal but coma persists | Specific imaging criteria; proactive re-imaging strategy; detect evolving injury |
| Brain MRI | Mentioned as useful | Extensive diffusion restriction at 2–7 days predicts poor outcome | Specific timing and pattern criteria; useful when CT inconclusive |
| Imaging expertise | General recommendation | NEW Emphasize evaluation by specialist with specific experience; consider telemedicine consultation where unavailable | Quality assurance for prognostication; reduce interpretation errors; expand access via telemedicine |
| Favorable predictors | Not systematically defined | NEW Formal favorable predictors introduced: GCS motor 4–5 at 72-96 h; NSE < 17 μg/L; continuous EEG; no DWI restriction on MRI | Balanced prediction of both poor and good outcomes; >80% recovery rate with ≥2 favorable signs; realistic family counseling |
| Indeterminate outcome | Not formally recognized | NEW Explicit indeterminate category when neither poor nor favorable signs predominate; recommend prolonged observation | Avoid premature WLST in uncertain cases; acknowledge prognostic uncertainty; define management pathway |
| Prognostication algorithm | Required ≥2 poor predictors | STRENGTHENED Requires ≥2 concordant predictors from multiple domains; can be poor OR favorable | Multimodal approach strengthened; recognize spectrum of outcomes; reduce errors |
 Supportive care | |||
| Prophylactic antibiotics | Standard ICU practice | AGAINST Recommend AGAINST routine use; low threshold for empiric treatment with clinical suspicion of pneumonia | Antibiotic stewardship; balance with high aspiration risk post-arrest; individualized approach |
| Stress ulcer prophylaxis | General ICU recommendation | STRONG Emphasized given high GI bleeding risk with antiplatelet/anticoagulant therapy | Proactive GI protection; recognize increased bleeding risk |
| Nutrition | Early enteral feeding | Start trophic feeding, increase gradually as tolerated | Early gut nutrition; avoid feeding intolerance; support metabolic recovery |
 Rehabilitation and follow-up | |||
| In-hospital rehabilitation | Mentioned briefly | COMPREHENSIVE Comprehensive guidance: early mobilization, delirium management, ICU diaries, physical/occupational/speech therapy | Systematic implementation; reduce post-intensive care syndrome; improve functional outcomes |
| Post-discharge follow-up | General recommendation | MANDATORY Mandatory within 3 months; structured screening for cognitive/emotional/physical impairments; multidisciplinary teams | Proactive long-term care; early detection of problems; coordinated intervention |
| co-survivor support | Not specifically addressed | NEW Formal recognition of co-survivors; psychological support; invitation to follow-up; screening for emotional problems | Address caregiver burden systematically; include family in recovery; prevent co-survivor distress |
| Patient information | General recommendation | SPECIFIC Specific information covering medical topics, resuming activities (driving, work, relationships, sexuality) | Comprehensive patient education; empower decision-making; facilitate return to normal life |
 Organ donation and registry reporting | |||
| Organ donation | Consider in appropriate circumstances | MANDATORY Mandatory evaluation of all post-arrest deaths; highlight 12.6% brain death overall and 27.9% after ECPR; active assessment in ECPR survivors | Systematic vs. opportunistic approach; maximize organ utilization; recognize ECPR as high brain death risk |
| Registry reporting | Report standard outcomes | NEW Registries should report organ donation after cardiac arrest | Improve data on donation rates; enable quality improvement |
Key changes from 2021 to 2025 ERC/ESICM post-resuscitation care guidelines.
Comprehensive comparison of key recommendations between 2021 and 2025 European Resuscitation Council and European Society of Intensive Care Medicine guidelines for post-resuscitation care.
TTM, targeted temperature management; SpO2, peripheral oxygen saturation; FiO2, fraction of inspired oxygen; ABG, arterial blood gas; MAP, mean arterial pressure; mmHg, millimeters of mercury; GCS, Glasgow Coma Scale; EEG, electroencephalography; SSEP, somatosensory evoked potentials; NMB, neuromuscular blockade; NSE, neuron-specific enolase; NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein; DWI, diffusion-weighted imaging; MRI, magnetic resonance imaging; CT, computed tomography; GM/WM, grey matter/white matter; WLST, withdrawal of life-sustaining therapy; ICU, intensive care unit; ARDS, acute respiratory distress syndrome; GI, gastrointestinal; ECPR, extracorporeal cardiopulmonary resuscitation; OHCA, out-of-hospital cardiac arrest; CTPA, computed tomography pulmonary angiography; ROSC, return of spontaneous circulation; ICP, intracranial pressure; μg/L, micrograms per liter; kPa, kilopascals.
Initial diagnostics and early management
The 2021 guidelines favored early coronary angiography in OHCA with suspected coronary cause and considered whole-body CT selectively. The 2025 guidelines recommend more selective invasive cardiology in non-ST-elevation OHCA, encouraging delayed or targeted angiography unless high suspicion exists, provide stronger endorsement of early comprehensive CT from head to pelvis when etiology is unclear, and show greater attention to post-ROSC myocardial dysfunction surveillance through routine echocardiography (7, 8). The clinical implication is to reduce non-beneficial early catheterization in non-ST-elevation patterns, broaden early search for non-coronary etiologies, and embed point-of-care echocardiography in the first hours.
Oxygenation and ventilation
The 2021 guidelines recommended avoiding hypoxia and hyperoxia, targeting SpO2 of 94–98%, and maintaining normocapnia. The 2025 guidelines reaffirm narrow oxygen targets with stronger caution against sustained hyperoxia, reinforce lung-protective ventilation and strict normocapnia, and provide a new warning about pulse oximetry overestimating oxygen saturation in darker skin tones (7, 8). The clinical implication is to titrate fraction of inspired oxygen quickly post-ROSC, proactively monitor arterial blood gases, be aware of pulse oximetry limitations, and avoid both hypocapnia and hypercapnia.
Hemodynamics and blood pressure targets
The 2021 guidelines generally recommended MAP at or above 65 mmHg with individualized targets discussed but not strongly qualified. The 2025 guidelines endorse MAP of 60–65 mmHg as default, based on individual patient data meta-analysis showing no global benefit of higher MAP greater than 71–85 mmHg, with more explicit criteria for individualization in chronic hypertension or organ hypoperfusion and acceptance of prehospital adrenaline infusions when noradrenaline unavailable (7, 8). The clinical implication is a shift from universal higher MAP to personalized moderate-intensity targets, sparing vasopressor burden in many patients while recognizing scenarios requiring higher MAP.
Temperature control
The 2021 guidelines recommended temperature control with either 33 or 36 degrees Celsius, acknowledging the TTM trial showing no difference between these targets. The 2025 guidelines pivot to universal fever prevention targeting temperature at or below 37.5 degrees Celsius for 36–72 h without routine hypothermia, rename the approach as temperature control versus targeted temperature management, and clearly advise against routine prehospital cooling with cold fluids (7, 8). The clinical implication represents a paradigm shift from active hypothermia induction to active fever prevention alone, simplifying protocols, reducing shivering burden, and minimizing physiological stress while retaining key neuroprotection. The TTM2 trial and subsequent analyses support equivalence of 33 versus normal temperatures with active fever prevention, and fever itself remains detrimental.
Seizure management
The 2021 guidelines encouraged continuous EEG for seizure detection and treated overt seizures with first- line levetiracetam or sodium valproate but were noncommittal on prophylaxis. The 2025 guidelines explicitly recommend against routine prophylactic antiseizure drugs, advocate treating only confirmed seizures on clinical examination or EEG, promote early EEG from day 1 to detect both seizures and prognostic markers such as background continuity and reactivity, emphasize wake-up trials in patients with myoclonus plus benign EEG, and recommend recording EEG during myoclonic jerks to identify any epileptiform correlate (7, 8). The clinical implication is to avoid medication side effects and sedation from unnecessary prophylaxis, focus treatment on proven seizures, and maximize early prognostic data from EEG while enabling earlier awakening trials.
Prognostication
The 2021 guidelines recommended multimodal prognostication at 72 h or later, combining clinical examination including pupillary and corneal reflexes, bilateral absence of N20 on SSEPs, specific malignant EEG patterns, NSE greater than 60 micrograms per liter at 48–72 h, status myoclonus, and imaging findings including CT or MRI. The 2025 guidelines lower the awakening threshold for prognostication from Glasgow Coma Scale motor less than or equal to 3 to motor less than 6, strongly recommend pupillometry for objective pupil assessment, downgrade EEG reactivity as a standalone poor-outcome predictor, clarify SSEP timing as acceptable from 24 h rather than requiring delay until 72 h, refine status myoclonus definition as continuous generalized myoclonus for 30 min or more within 72 h, introduce formal favorable predictors including Glasgow Coma Scale motor 4–5 at 72–96 h, NSE less than 17 micrograms per liter, continuous EEG background without discharges, and absence of diffusion restriction on MRI, emphasize indeterminate outcome category when neither poor nor favorable signs predominate, and recommend repeat imaging at 72–96 h if initial CT is normal but coma persists (7, 8). The clinical implication is broader eligibility for prognostication capturing more patients, standardized pupil measurement reducing inter-rater variability, earlier SSEP feasibility, balanced prediction of both poor and good outcomes to guide realistic family counseling, and defined pathway for uncertain cases including re- imaging and prolonged observation rather than premature withdrawal.
Sedation and neuromuscular blockade
The 2021 guidelines recommended short-acting sedation to enable neurological assessment and selective neuromuscular blockade only when indicated. The 2025 guidelines strengthen recommendations for daily sedation holds and early neurological examination, explicitly state against routine neuromuscular blockade as it obscures seizures and clinical signs, and restrict paralysis to severe ARDS, refractory status epilepticus, or shivering during active cooling (7, 8). The clinical implication is greater emphasis on wake-up trials enabling earlier prognostic clarity and potentially shorter ICU stays while minimizing risks of prolonged paralysis.
General care
The 2021 guidelines recommended standard ICU supportive care including glycemic control, nutrition, and infection prevention. The 2025 guidelines add explicit recommendations against routine prophylactic antibiotics, favor low threshold for empiric antibiotics with clinical suspicion of pneumonia particularly given aspiration risk, recommend early trophic enteral feeding with gradual advancement, and emphasize stress ulcer prophylaxis given high gastrointestinal bleeding risk with antiplatelet or anticoagulation therapy (7, 8). The clinical implication is antibiotic stewardship balanced with vigilance for post-arrest aspiration pneumonia, early gut nutrition supporting metabolic recovery, and proactive gastrointestinal protection.
Rehabilitation and long-term care
The 2021 guidelines mentioned rehabilitation and follow-up briefly without detailed recommendations. The 2025 guidelines introduce comprehensive guidance for in-hospital early mobilization, delirium management, and ICU diaries, mandate structured follow-up within 3 months post-discharge screening for cognitive, emotional, and physical impairments, recommend multidisciplinary rehabilitation teams, formally recognize co-survivors requiring psychological support and inclusion in follow-up, and specify providing detailed information on resuming activities including driving, work, and relationships (7, 8). The clinical implication represents a major expansion of post-ICU care continuum, addressing post-intensive care syndrome, supporting caregiver burden, and optimizing functional recovery and quality of life beyond hospital survival.
Organ donation
The 2021 guidelines mentioned organ donation consideration in appropriate circumstances. The 2025 guidelines mandate evaluation of all post-cardiac arrest deaths for donation eligibility, highlight 12.6% brain death prevalence overall and 27.9% after ECPR, recommend active brain death assessment in comatose ECPR survivors, suggest considering donation after circulatory determination of death when life- sustaining treatment is withdrawn, and require cardiac arrest registries to report donation outcomes (7, 8). The clinical implication is systematic rather than opportunistic donation evaluation, recognition of ECPR as high brain death risk warranting proactive assessment, and improved organ utilization from cardiac arrest deaths.
Conclusion
The 2025 ERC/ESICM guidelines for post-resuscitation care represent a significant evolution in the management of comatose cardiac arrest survivors, emphasizing evidence-based neuroprotection through rigorous fever prevention rather than routine hypothermia, individualized hemodynamic management targeting moderate mean arterial pressure of 60–65 mmHg, balanced oxygenation with awareness of pulse oximetry limitations, and selective rather than prophylactic antiseizure medication use. The refined multimodal prognostication algorithm incorporates both poor and favorable outcome predictors, requires assessment at 72 h or later with exclusion of all confounders, mandates concordance of at least two predictors to minimize false-positive predictions of poor outcome, and introduces formal recognition of indeterminate outcomes requiring prolonged observation. Perhaps most notably, the 2025 guidelines expand the continuum of care beyond the ICU phase, establishing comprehensive rehabilitation pathways, structured 3-month follow-up assessments for both survivors and co-survivors, and systematic evaluation for organ donation in all appropriate cases. Implementation of this integrated multimodal framework offers clinicians the optimal evidence-based approach to maximize neurological recovery, provide accurate prognostic information to families, avoid premature withdrawal of life-sustaining therapy, and improve long-term functional outcomes and quality of life for cardiac arrest survivors.
Statements
Author contributions
SK: Writing – review & editing, Software, Validation, Resources, Formal analysis, Investigation, Data curation, Funding acquisition, Methodology, Visualization, Writing – original draft, Supervision, Conceptualization, Project administration. PN: Supervision, Writing – review & editing, Validation.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
ViraniSSAlonsoABenjaminEJBittencourtMSCallawayCWCarsonAPet al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. (2020) 141:e139–596. doi: 10.1161/CIR.0000000000000757,
2.
AndersenLWHolmbergMJBergKMDonninoMWGranfeldtA. In-hospital cardiac arrest: a review. JAMA. (2019) 321:1200–10. doi: 10.1001/jama.2019.1696,
3.
LaverSFarrowCTurnerDNolanJ. Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Med. (2004) 30:2126–8. doi: 10.1007/s00134-004-2425-z,
4.
NeumarRWNolanJPAdrieCAibikiMBergRABöttigerBWet al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the international liaison committee on resuscitation. Circulation. (2008) 118:2452–83. doi: 10.1161/CIRCULATIONAHA.108.190652
5.
SekhonMSAinsliePNGriesdaleDE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a "two-hit" model. Crit Care. (2017) 21:90. doi: 10.1186/s13054-017-1670-9,
6.
GeocadinRGCallawayCWFinkELGolanEGreerDMKoNUet al. Standards for studies of neurological prognostication in comatose survivors of cardiac arrest: a scientific statement from the American Heart Association. Circulation. (2019) 140:e517–42. doi: 10.1161/CIR.0000000000000702,
7.
NolanJPSandroniCBöttigerBWCariouACronbergTFribergHet al. European resuscitation council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care. Resuscitation. (2021) 161:220–69. doi: 10.1016/j.resuscitation.2021.02.012,
8.
NolanJPSandroniCAndersenLWBöttigerBWCariouACronbergTet al. European resuscitation council and European Society of Intensive Care Medicine Guidelines 2025: post-resuscitation care. Resuscitation. (2025) 206:110465. doi: 10.1016/j.resuscitation.2025.110465
9.
PosnerJBSaperCBSchiffNDPlumF. Plum and Posner's diagnosis of stupor and coma. 4th ed Oxford University Press (2007).
10.
PlumFPosnerJB. The diagnosis of stupor and coma. 1st ed FA Davis Company (1972).
11.
KilgannonJHJonesAEShapiroNIAngelosMGMilcarekBHunterKet al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA. (2010) 303:2165–71. doi: 10.1001/jama.2010.707,
12.
LiptonP. Ischemic cell death in brain neurons. Physiol Rev. (1999) 79:1431–568. doi: 10.1152/physrev.1999.79.4.1431,
13.
AdrieCAdib-ConquyMLaurentIMonchiMVinsonneauCFittingCet al. Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation. (2002) 106:562–8. doi: 10.1161/01.cir.0000023891.80661.ad,
14.
HendrickxHHRaoGRSafarPGisvoldSE. Asphyxia, cardiac arrest and resuscitation in rats. I. Short term recovery. Resuscitation. (1984) 12:97–116. doi: 10.1016/0300-9572(84)90062-5
15.
IidaKSatohHAritaKNakaharaTKurisuKOhtaniM. Delayed hyperemia causing intracranial hypertension after cardiopulmonary resuscitation. Crit Care Med. (1997) 25:971–6. doi: 10.1097/00003246-199706000-00011,
16.
SundgreenCLarsenFSHerzogTMKnudsenGMBoesgaardSAldershvileJ. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke. (2001) 32:128–32. doi: 10.1161/01.str.32.1.128,
17.
CallawayCWDonninoMWFinkELGeocadinRGGolanEKernKBet al. Part 8: post-cardiac arrest care: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. (2015) 132:S465–82. doi: 10.1161/CIR.0000000000000262,
18.
TomteOAndersenGOJacobsenDDraegniTAuestadBSundeK. Strong and weak aspects of an established post-resuscitation treatment protocol—a five-year observational study. Resuscitation. (2011) 82:1186–93. doi: 10.1016/j.resuscitation.2011.05.003,
19.
RobertsBWKilgannonJHChanskyMEMittalNWoodenJTrzeciakS. Association between postresuscitation partial pressure of arterial carbon dioxide and neurological outcome in patients with post-cardiac arrest syndrome. Circulation. (2013) 127:2107–13. doi: 10.1161/CIRCULATIONAHA.112.000168,
20.
SchneiderAGEastwoodGMBellomoRBaileyMLipcseyMPilcherDet al. Arterial carbon dioxide tension and outcome in patients admitted to the intensive care unit after cardiac arrest. Resuscitation. (2013) 84:927–34. doi: 10.1016/j.resuscitation.2013.02.014,
21.
SutherasanYVargasMPelosiP. Protective mechanical ventilation in the non-injured lung: review and meta-analysis. Crit Care. (2014) 18:211. doi: 10.1186/cc13778,
22.
LaurentIMonchiMChicheJDJolyL-MSpauldingCBourgeoisBéet al. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. J Am Coll Cardiol. (2002) 40:2110–6. doi: 10.1016/s0735-1097(02)02594-9,
23.
JaniczekJAWingerDGCopplerPSabedraAMurrayHPermanSMet al. Association between hemodynamic interventions and outcomes in cardiac arrest: a systematic review and meta-analysis. Resuscitation. (2023) 193:110004
24.
BergKMBrayJENgKCLileyHGGreifRCarlsonJNet al. 2023 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations: summary from the basic life support; advanced life support; pediatric life support; neonatal life support; education, implementation, and teams; and first aid task forces. Circulation. (2023) 148:e187–280. doi: 10.1161/CIR.0000000000001179,
25.
SoarJBöttigerBWCarliPCouperKDeakinCDDjärvTet al. European resuscitation council guidelines 2021: adult advanced life support. Resuscitation. (2021) 161:115–51. doi: 10.1016/j.resuscitation.2021.02.010,
26.
ChoudharyRStigaNPerkinsGDLockeyD. Adrenaline versus noradrenaline in cardiac arrest: a systematic review and individual patient data meta-analysis. Resuscitation. (2022) 178:82–9. doi: 10.1016/j.resuscitation.2022.04.024
27.
ChalkiasAXanthosT. Pathophysiology and pathogenesis of post-resuscitation myocardial stunning. Heart Fail Rev. (2012) 17:117–28.
28.
DankiewiczJCronbergTLiljaGJakobsenJCLevinHUllénSet al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. (2021) 384:2283–94. doi: 10.1056/NEJMoa2100591,
29.
RossettiAORabinsteinAAOddoM. Neurological prognostication of outcome in patients in coma after cardiac arrest. Lancet Neurol. (2016) 15:597–609. doi: 10.1016/S1474-4422(16)00015-6,
30.
WijdicksEFParisiJESharbroughFW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol. (1994) 35:239–43. doi: 10.1002/ana.410350219
31.
LanceJWAdamsRD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain. (1963) 86:111–36. doi: 10.1093/brain/86.1.111
32.
RossettiAOLogroscinoGLiaudetLRuffieuxCRibordyVSchallerMDet al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. (2007) 69:255–60. doi: 10.1212/WNL.69.3.255
33.
HirschLJLaRocheSMGaspardNGerardESvoronosAHermanSTet al. American clinical neurophysiology society's standardized critical care EEG terminology: 2012 version. J Clin Neurophysiol. (2013) 30:1–27. doi: 10.1097/WNP.0b013e3182784729,
34.
KrumholzASternBJWeissHD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology. (1988) 38:401–5. doi: 10.1212/WNL.38.3.401
35.
BjellandTWDaleOKaisenKHaugenBOLydersenSStrandKet al. Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: a randomised trial. Intensive Care Med. (2012) 38:959–67. doi: 10.1007/s00134-012-2540-1,
36.
LeithnerCPlonerCJHasperDStormC. Does hypothermia influence the predictive value of bilateral absent N20 after cardiac arrest?Neurology. (2010) 74:965–9. doi: 10.1212/WNL.0b013e3181d5a631,
37.
PerbetSMongardonNDumasFBruelCLemialeVMourvillierBet al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med. (2011) 184:1048–54. doi: 10.1164/rccm.201102-0331OC,
38.
JennettBBondM. Assessment of outcome after severe brain damage. Lancet. (1975) 1:480–4.
39.
WilsonJTPettigrewLETeasdaleGM. Structured interviews for the Glasgow outcome scale and the extended Glasgow outcome scale: guidelines for their use. J Neurotrauma. (1998) 15:573–85. doi: 10.1089/neu.1998.15.573,
40.
SandroniCD'ArrigoSNolanJP. Prognostication after cardiac arrest. Crit Care. (2018) 22:150. doi: 10.1186/s13054-018-2060-7,
41.
GiacinoJTKatzDISchiffNDWhyteJAshmanEJAshwalSet al. Practice guideline update recommendations summary: disorders of consciousness: report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of neurology; the American congress of rehabilitation medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology. (2018) 91:450–60. doi: 10.1212/WNL.0000000000005926
42.
KondziellaDBenderADiserensKvan ErpWEstraneoAFormisanoRet al. European academy of neurology guideline on the diagnosis of coma and other disorders of consciousness. Eur J Neurol. (2020) 27:741–56. doi: 10.1111/ene.14151,
43.
ElmerJScutellaMPullalarevuRWangBVaghasiaNTrzeciakSet al. The association between hyperoxia and patient outcomes after cardiac arrest: analysis of a high-resolution database. Intensive Care Med. (2015) 41:49–57. doi: 10.1007/s00134-014-3555-6,
44.
BodienYGBarraATemkinNRBarberJForemanBVassarMet al. Diagnosing level of consciousness: the limits of the Glasgow coma scale Total score. J Neurotrauma. (2021) 38:3295–305. doi: 10.1089/neu.2021.0199,
Summary
Keywords
brain injuries, critical care, heart arrest, post-cardiac arrest syndrome, prognosis
Citation
Kortli S and Nasa P (2026) The neurological phoenix: multimodal strategies for brain recovery and prognostication in post-cardiac arrest syndrome—a 2025 clinical framework. Front. Med. 13:1775538. doi: 10.3389/fmed.2026.1775538
Received
25 December 2025
Revised
17 January 2026
Accepted
23 January 2026
Published
18 March 2026
Volume
13 - 2026
Edited by
Jian-Xin Zhou, Capital Medical University, China
Reviewed by
Brooke Murtaugh, Madonna Rehabilitation Hospital, United States
Sohma Miyamoto, St Luke's International Hospital, Japan
Updates
Copyright
© 2026 Kortli and Nasa.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Said Kortli, kortlisaid@outlook.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.